The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type

This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA during 2016. The different drugs from the 2016 “harvest” have been classified according to their chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural products; drug combina...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Torre, Beatriz G., Albericio, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155368/
https://www.ncbi.nlm.nih.gov/pubmed/28264468
http://dx.doi.org/10.3390/molecules22030368
_version_ 1783357886873731072
author de la Torre, Beatriz G.
Albericio, Fernando
author_facet de la Torre, Beatriz G.
Albericio, Fernando
author_sort de la Torre, Beatriz G.
collection PubMed
description This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA during 2016. The different drugs from the 2016 “harvest” have been classified according to their chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural products; drug combination; and small molecules.
format Online
Article
Text
id pubmed-6155368
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61553682018-11-13 The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type de la Torre, Beatriz G. Albericio, Fernando Molecules Review This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA during 2016. The different drugs from the 2016 “harvest” have been classified according to their chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural products; drug combination; and small molecules. MDPI 2017-02-27 /pmc/articles/PMC6155368/ /pubmed/28264468 http://dx.doi.org/10.3390/molecules22030368 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
de la Torre, Beatriz G.
Albericio, Fernando
The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title_full The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title_fullStr The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title_full_unstemmed The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title_short The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type
title_sort pharmaceutical industry in 2016. an analysis of fda drug approvals from a perspective of the molecule type
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155368/
https://www.ncbi.nlm.nih.gov/pubmed/28264468
http://dx.doi.org/10.3390/molecules22030368
work_keys_str_mv AT delatorrebeatrizg thepharmaceuticalindustryin2016ananalysisoffdadrugapprovalsfromaperspectiveofthemoleculetype
AT albericiofernando thepharmaceuticalindustryin2016ananalysisoffdadrugapprovalsfromaperspectiveofthemoleculetype
AT delatorrebeatrizg pharmaceuticalindustryin2016ananalysisoffdadrugapprovalsfromaperspectiveofthemoleculetype
AT albericiofernando pharmaceuticalindustryin2016ananalysisoffdadrugapprovalsfromaperspectiveofthemoleculetype

Ejemplares similares